Advancing immunotherapy for early-stage triple-negative breast cancer

Neoadjuvant chemotherapy is increasingly used in early-stage triple-negative breast cancer given that chemotherapy is inevitable and tumour response assessment from surgical specimens provides prognostic information. 1 National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology. Breast cancer. V52·020. https://www.nccn.org/professionals/physician_gls/Date accessed: September 16, 2020 Google Scholar A US Food and Drug...